CN110384746A - A kind of pharmaceutical composition and its preparation method and application preventing and treating gout - Google Patents
A kind of pharmaceutical composition and its preparation method and application preventing and treating gout Download PDFInfo
- Publication number
- CN110384746A CN110384746A CN201910786722.7A CN201910786722A CN110384746A CN 110384746 A CN110384746 A CN 110384746A CN 201910786722 A CN201910786722 A CN 201910786722A CN 110384746 A CN110384746 A CN 110384746A
- Authority
- CN
- China
- Prior art keywords
- parts
- portions
- radix
- pharmaceutical composition
- gout
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 76
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 39
- 239000002994 raw material Substances 0.000 claims abstract description 33
- 239000000284 extract Substances 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 21
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 20
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 20
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 20
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 20
- 241000205407 Polygonum Species 0.000 claims abstract description 20
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 20
- 244000197580 Poria cocos Species 0.000 claims abstract description 20
- 240000004980 Rheum officinale Species 0.000 claims abstract description 20
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 20
- 239000012530 fluid Substances 0.000 claims abstract description 20
- 241000967218 Selaginella tamariscina Species 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000009835 boiling Methods 0.000 claims abstract description 16
- 239000000706 filtrate Substances 0.000 claims abstract description 14
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 238000012856 packing Methods 0.000 claims abstract description 7
- 238000010992 reflux Methods 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 7
- 241000218628 Ginkgo Species 0.000 claims description 19
- 241000202807 Glycyrrhiza Species 0.000 claims description 18
- 241001078983 Tetradium ruticarpum Species 0.000 claims description 14
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000005913 Maltodextrin Substances 0.000 claims description 6
- 229920002774 Maltodextrin Polymers 0.000 claims description 6
- 238000007654 immersion Methods 0.000 claims description 6
- 229940035034 maltodextrin Drugs 0.000 claims description 6
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 2
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 2
- 240000001851 Artemisia dracunculus Species 0.000 claims description 2
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 2
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 2
- 241000207929 Scutellaria Species 0.000 claims description 2
- 229960002708 antigout preparations Drugs 0.000 claims description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract 1
- 239000003818 cinder Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 34
- 239000003814 drug Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 229940079593 drug Drugs 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 14
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 14
- 229940116269 uric acid Drugs 0.000 description 14
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 238000002386 leaching Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 229940075420 xanthine Drugs 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000026816 acute arthritis Diseases 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KKADPXVIOXHVKN-UHFFFAOYSA-N 4-hydroxyphenylpyruvic acid Chemical compound OC(=O)C(=O)CC1=CC=C(O)C=C1 KKADPXVIOXHVKN-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000218691 Cupressaceae Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 206010046337 Urate nephropathy Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical compound [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 208000009928 nephrosis Diseases 0.000 description 1
- 231100001027 nephrosis Toxicity 0.000 description 1
- 235000020823 overnutrition Nutrition 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000007968 uric acids Chemical class 0.000 description 1
- 235000003563 vegetarian diet Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention particularly discloses a kind of pharmaceutical compositions and its preparation method and application for preventing and treating gout；The pharmaceutical composition that the present invention prevents and treats gout includes following raw material: Selaginella tamariscina, polygonum cuspidate, rheum officinale, ginkgo leaf, Radix Salviae Miltiorrhizae, radix paeoniae rubra, the coptis, Radix Glycyrrhizae, Poria cocos and auxiliary material are several.The pharmaceutical composition preparation method of the prevention and treatment gout comprises the steps of: that S1. carries out raw material screening by formula, and gets out various raw material；S2. 30~45min will be impregnated in various medicinal material warm water；S3. above-mentioned various medicinal materials are subjected to refluxing extraction, first high-temperature boiling is decocted followed in turn by small fire；S4. then, melt cinder separates, and collects medical fluid, continues to extract the dregs of a decoction 1~3 time；S5. finally, taking filtrate, filter residue, merging filtrate are abandoned；S6. medical fluid is condensed into the medicinal extract that density is 1.25~1.35；S7. then, it is pelletized by granulator, tabletting and packing to get.
Description
Technical field
The present invention relates to pharmaceutical formulation techniques fields, and in particular to it is a kind of prevent and treat gout pharmaceutical composition and its
Preparation method and application.
Background technique
In recent years, with the development of the social economy, people's lives level and eating condition are greatly improved, drink
Food structure is obviously improved, and the ratio that meat accounts for obviously increases, and vegetarian diet accounting tails off, and diet occurs so as to cause many people
Structure is unbalanced, and diet intake is excessively greasy, and the case where overnutrition occurs in body, while operating pressure is big now, overtime work compared with
It is more, lead to most enough movements of people's long-term lacking, also constantly declines so as to cause physical fitness, passive protective physical fitness is gradually
Weaken；And now in food the illegal addition of additive and abuse and fast food culture it is prevailing, these are all in food
Nutriment produce destruction, cause people the deficiency of some nutriments occur, and then generate to the health of people
Injury, and the metabolism for resulting in some substances gets muddled, gout is exactly the caused disease because of disorders of purine metabolism, and
Has the tendency that rejuvenation.
Gout is the inflammatory joint diseases caused by monosodium urate mineralization is in joint or periarticular, with purine metabolism
Hyperuricemia caused by disorder, underexcretion or internal uric acid increase is directly related.So hyperuricemia is gout
The principal element of development, the uric acid level of male are higher than 420 μm of ol/L, and the uric acid level of women is higher than 360 μm of ol/L, that is, diagnoses
For hyperuricemia.About 5%~12% Patients with Hyperuricemia can develop into gout.The main clinical characteristics of acute gout
It is acute arthritis and chronic gout stone disease, mainly includes acute attack arthritis, tophaceous chornic arthritis, uric acid
Salt nephrosis and uric acid lithangiuria.
For modern medicine according to goat because of difference, gout can be divided into primary gout and secondary gout two major classes.It is primary
Property gout refers on the basis of excluding other diseases, because of pain caused by congenital purine metabolic disturbance or uric acid excretion disorder
Wind.Hair property gout refers to secondary to underexcretion caused by kidney trouble or some drugs, myeloproliferative disease and tumour
The generation of uric acid caused by chemotherapy increase etc. caused by gout.
The main clinical characteristics of acute gout are acute arthritis and chronic gout stone disease, mainly include acute attack
Arthritis, tophaceous chornic arthritis, urate nephropathy and uric acid lithangiuria.Symptom when gout initial onset is anxious
Property urarthritis, shows as the arthralgia in one or more joints of night-time attack；Severe pain when gout is broken out,
Serious influence can be usually caused on the life and work of patient with gout, it is serious to even result in can't take care of oneself for patient, sternly
Ghost image rings the life quality of patient.Also, as the development of gout is also possible to that patient is caused some complication occur, including normal
Kidney trouble, diabetes and the cardiovascular disease and metabolic syndrome seen.Therefore, gout has become at present influences people
One of the disease of health.
But at present clinically for gout based on the Western medicine such as colchicin, phenylbutazone and brufen, for alleviating
Related symptoms reduce uric acid, and still, these Western medicine are mainly used for the symptom of acute alleviation gout, can not fundamentally control
More gout needs to take for a long time, and treatment gets up to be more troublesome；Also, these Western medicine also result in a series of during taking
It is bad anti-, it will also result in certain influence to hepatic and renal function, side effect is larger, this is used to patient and the process of clinical treatment increases
Trouble is added.
Traditional Chinese medicine points out the card of gout category beriberoid pyretic arthralgia, shows as obstructed, heat evil stasis blocking of retention of damp-heat in the interior, qi and blood etc., in
Doctor has had gout clinical symptoms the experience of certain research and treatment；But currently, in the market for treating gout
Special Chinese medicinal formulae is also less, and the therapeutic effect of prescription is ideal not enough.
Summary of the invention
For current in the market for preventing and treating the case where Traditional Chinese medicine composition of gout more lacks, this makes
To clinically for the effect of gout treatment produce it is certain restrict and limitation, to consolidating the therapeutic effect of gout for a long time also not to the utmost
Ideal problem it is an object of that present invention to provide a kind of pharmaceutical composition for preventing and treating gout and preparation method thereof and is answered
With.
Currently, the drug for the treatment of gout clinically is not able to satisfy associated treatment demand, model is treated for further expansion
It encloses and is restricted, be not able to satisfy relevant curative effect demand；Selaginella tamariscina has effects that blood circulation；Polygonum cuspidate is dispelled with heat-clearing
It is wet, the effect of removing blood stasis and acesodyne；Rheum officinale has clearing heat-fire, the effect of dispelling stasis of blood and stimulating the menstrual flow；Ginkgo leaf has activating microcirculation and removing stasis medicinal, removes obstruction in channels to relieve pain
The effect of；Radix Salviae Miltiorrhizae has effects that activating microcirculation and removing stasis medicinal, dredging collateral swelling and pain relieving；Radix paeoniae rubra has clearing heat and cooling blood, stasis-dispelling and pain-killing effect；Coptis tool
There is the effect of heat-clearing and damp-drying drug；It is sweet slow that Radix Glycyrrhizae has temperature to dissipate, the effect of energy and inverse gas: Poria cocos has effects that Li Shui dehumidifying；Passing through will
The effect of can not only playing drug alone is used in conjunction in above-mentioned Chinese medicine, can preferably play and enhance various Chinese medicines by combination
Effect can play the role of better analgesic, anti-inflammatory, dispelling stasis of blood and stimulating the menstrual flow and resistance building；Meanwhile passing through this preparation method
A kind of pharmaceutical composition stability of prevention and treatment gout of preparation is good, is convenient for daily preservation management；And with commercially available part
The composition for the treatment of gout have the effect of that the gout preferably treated, curative effect are more thorough compared to composition prepared by the present invention
Bottom, it is uneasy to recur, and also safety is more preferable, and adverse reaction is few, and for a wider population, clinical treatment preferably uses, and more can
Guarantee the safety of patient, and crowd high for uric acid takes, and can reduce uric acid, the wind that prevention gout occurs can be played
Danger.Thus the present invention not only can solve the west for the treatment of gout now by developing a kind of pharmaceutical composition of prevention and treatment gout
Medicine is palliative, and curative effect is not lasting enough, is easy recurrence and the more problem of side effect, is more able to satisfy the needs of clinical treatment.
To realize that above-mentioned target, the present invention are achieved by the following technical programs:
A kind of pharmaceutical composition preventing and treating gout, by weight score meter are made of following raw material: 4~11 parts of volumes
Cypress, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9 parts of coptiss, 3
~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos and auxiliary material are several.
Preferably, the pharmaceutical composition of a kind of prevention and treatment gout, score meter is by following raw material group by weight
At: 4~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3
~9 portions of coptiss, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas and auxiliary material are several.
Preferably, the pharmaceutical composition of a kind of prevention and treatment gout, score meter is by following raw material group by weight
At: 4~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3
~9 portions of coptiss, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 parts of radix scutellariaes and auxiliary material are several.
Preferably, the pharmaceutical composition of a kind of prevention and treatment gout, score meter is by following raw material group by weight
At: 4~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3
~9 portions of coptiss, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 parts of rhizoma atractylodis and auxiliary material are several.
Preferably, the pharmaceutical composition of a kind of prevention and treatment gout, score meter is by following raw material group by weight
At: 4~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3
~9 portions of coptiss, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 portions of rhizoma alismatis and auxiliary material are several.
Preferably, the pharmaceutical composition of a kind of prevention and treatment gout, score meter is by following raw material group by weight
At: 4~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3
If~9 portions of coptiss, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 portions of rhizoma alismatis, 3~8 portions of oriental wormwoods and auxiliary material
It is dry.
Preferably, the pharmaceutical composition of a kind of prevention and treatment gout, score meter is by following raw material group by weight
At: 4~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3
If~9 portions of coptiss, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 portions of rhizoma alismatis, 3~10 parts of Radix Astragalis and auxiliary material
It is dry.
Preferably, the auxiliary material is maltodextrin and sucrose.
It is highly preferred that the maltodextrin and sucrose ratio are 1~1.2:2.5~4.
Preferably, the pharmaceutical composition preparation method of a kind of prevention and treatment gout comprising the steps of:
S1. raw material screening is carried out by formula, and gets out various raw material；
S2. it by various medicinal materials, is crushed, and impregnates 30~45min in warm water；
S3. the medicinal material after above-mentioned immersion is subjected to refluxing extraction, first high-temperature boiling, until 5~10min is kept after boiling, with
35~50min is decocted with 50~60 DEG C of small fires again afterwards；
S4. then, medical fluid and the dregs of a decoction are separated, collects medical fluid, the water for continuing to measure the dregs of a decoction with 8~12 times extracts the dregs of a decoction, first
It boils, then keeps the temperature at 70~85 DEG C, extract 50~60min, extract 2~3 times；
S5. then, filtrate is taken, filter residue is abandoned, medical fluid is condensed into the leaching that density is 1.25~1.35 (60 DEG C) by merging filtrate
Cream；
S6. then, medicinal extract is mixed with auxiliary material, pelletized by granulator, tabletting and packing to get.
Preferably, the pharmaceutical composition of the prevention and treatment gout is used to prepare prevention and anti-gout drugs.
Specific embodiment
The present invention is further elaborated combined with specific embodiments below, the embodiment is served only for explaining this hair
It is bright, it is not intended to limit the scope of the present invention.Test method as used in the following examples is routine unless otherwise specified
Method；Used material, reagent etc., unless otherwise specified, for the reagent and material commercially obtained.
Embodiment 1
A kind of pharmaceutical composition preventing and treating gout, by weight score meter are made of following raw material: 5 portions of Selaginella tamariscinas, 6 parts
Polygonum cuspidate, 3 parts of rheum officinales, 6 parts of ginkgo leaves, 8 parts of Radix Salviae Miltiorrhizaes, 5 parts of radix paeoniae rubras, 3 portions of coptiss, 4 portions of Radix Glycyrrhizaes, 5 parts of Poria cocos, maltodextrin and sucrose
It is several.
A kind of pharmaceutical composition preparation method preventing and treating gout comprising the steps of:
S1. raw material screening is carried out by formula, and gets out various raw material；
S2. it by various medicinal materials, is crushed, and impregnates 30min in warm water；
S3. the medicinal material after above-mentioned immersion is subjected to refluxing extraction, first high-temperature boiling, until keeping 5min after boiling, then again
35min is decocted with 50~60 DEG C of small fires；
S4. then, medical fluid and the dregs of a decoction being separated, collects medical fluid, the water for continuing to measure the dregs of a decoction with 8 times extracts the dregs of a decoction, first boils,
70 DEG C are then kept the temperature at, 50min is extracted, is extracted 2 times；
S5. then, filtrate is taken, filter residue is abandoned, medical fluid is condensed into the leaching that density is 1.25~1.35 (60 DEG C) by merging filtrate
Cream；
S6. then, medicinal extract is mixed with auxiliary material, pelletized by granulator, tabletting and packing to get.
Embodiment 2
A kind of pharmaceutical composition preventing and treating gout, by weight score meter are made of following raw material: 6 portions of Selaginella tamariscinas, 5 parts
Polygonum cuspidate, 5 parts of rheum officinales, 7 parts of ginkgo leaves, 9 parts of Radix Salviae Miltiorrhizaes, 8 parts of radix paeoniae rubras, 5 portions of coptiss, 6 portions of Radix Glycyrrhizaes, 6 parts of Poria cocos, 4 parts of evodia rutaecarpas, malt
Dextrin and sucrose are several.
A kind of pharmaceutical composition preparation method preventing and treating gout comprising the steps of:
S1. raw material screening is carried out by formula, and gets out various raw material；
S2. it by various medicinal materials, is crushed, and impregnates 35min in warm water；
S3. the medicinal material after above-mentioned immersion is subjected to refluxing extraction, first high-temperature boiling, until keeping 7min after boiling, then again
40min is decocted with 55 DEG C of small fires；
S4. then, medical fluid and the dregs of a decoction are separated, collects medical fluid, the water for continuing to measure the dregs of a decoction with 10 times extracts the dregs of a decoction, first boils
Boiling then keeps the temperature at 75 DEG C, extracts 55min, extracts 2 times；
S5. then, filtrate is taken, filter residue is abandoned, medical fluid is condensed into the leaching that density is 1.25~1.35 (60 DEG C) by merging filtrate
Cream；
S6. then, medicinal extract is mixed with auxiliary material, pelletized by granulator, tabletting and packing to get.
Embodiment 3
A kind of pharmaceutical composition preventing and treating gout, by weight score meter are made of following raw material: 7 portions of Selaginella tamariscinas, 5 parts
Polygonum cuspidate, 6 parts of rheum officinales, 10 parts of ginkgo leaves, 10 parts of Radix Salviae Miltiorrhizaes, 5 parts of radix paeoniae rubras, 4 portions of coptiss, 5 portions of Radix Glycyrrhizaes, 5 parts of Poria cocos, 6 parts of evodia rutaecarpas, 5
Part radix scutellariae, maltodextrin and sucrose are several.
A kind of pharmaceutical composition preparation method preventing and treating gout comprising the steps of:
S1. raw material screening is carried out by formula, and gets out various raw material；
S2. it by various medicinal materials, is crushed, and impregnates 38min in warm water；
S3. the medicinal material after above-mentioned immersion is subjected to refluxing extraction, first high-temperature boiling, until keeping 10min after boiling, then again
35min is decocted with 60 DEG C of small fires；
S4. then, medical fluid and the dregs of a decoction are separated, collects medical fluid, the water for continuing to measure the dregs of a decoction with 10 times extracts the dregs of a decoction, first boils
Boiling then keeps the temperature at 75 DEG C, extracts 50min, extracts 3 times；
S5. then, filtrate is taken, filter residue is abandoned, medical fluid is condensed into the leaching that density is 1.25~1.35 (60 DEG C) by merging filtrate
Cream；
S6. then, medicinal extract is mixed with auxiliary material, pelletized by granulator, tabletting and packing to get.
Embodiment 4
A kind of pharmaceutical composition preventing and treating gout, by weight score meter are made of following raw material: 8 parts of Selaginella tamariscinas, 10
Part polygonum cuspidate, 6 parts of rheum officinales, 10 parts of ginkgo leaves, 9 parts of Radix Salviae Miltiorrhizaes, 10 parts of radix paeoniae rubras, 8 portions of coptiss, 9 portions of Radix Glycyrrhizaes, 10 parts of Poria cocos, 8 parts of Wu Zhu
Cornel, 5 parts of rhizoma atractylodis, maltodextrin and sucrose are several.
A kind of pharmaceutical composition preparation method preventing and treating gout comprising the steps of:
S1. raw material screening is carried out by formula, and gets out various raw material；
S2. it by various medicinal materials, is crushed, and impregnates 42min in warm water；
S3. the medicinal material after above-mentioned immersion is subjected to refluxing extraction, first high-temperature boiling, until keeping 7min after boiling, then again
45min is decocted with 55 DEG C of small fires；
S4. then, medical fluid and the dregs of a decoction are separated, collects medical fluid, the water for continuing to measure the dregs of a decoction with 12 times extracts the dregs of a decoction, first boils
Boiling then keeps the temperature at 80 DEG C, extracts 55min, extracts 3 times；
S5. then, filtrate is taken, filter residue is abandoned, medical fluid is condensed into the leaching that density is 1.25~1.35 (60 DEG C) by merging filtrate
Cream；
S6. then, medicinal extract is mixed with auxiliary material, pelletized by granulator, tabletting and packing to get.
One, Studies on Animal Models of Hyperuricemic Mice test is caused for xanthine
Test object and drug: taking healthy mice, and 200 ± 5g of weight, is randomly divided into 6 groups by 60；Take the embodiment of the present invention
2 sample is dense during test group 1 is high concentration dosage group (suitable crude drug amount 15g/75ml), test group 2 is as test group 1~3
Spend dosage group (suitable crude drug amount 10g/75ml) and 3 low concentration dosage group of test group (suitable crude drug amount 5g/75ml), commercially available famous
Treat the prescription of gout as a control group, Normal group and model control group.
After mouse is raised 1 week, stomach-filling gives distilled water, distilled water, the commercially available famous prescription for treating gout to each group respectively
(by 3 times of normal dose), test group 1 are high concentration dosage group (suitable crude drug amount 15g/75ml), test group 2 is middle concentration agent
Amount group (suitable crude drug amount 10g/75ml) and 3 low concentration dosage group of test group (suitable crude drug amount 5g/75ml)；Press weight
0.3ml/10g stomach-filling, 2 times a day, for three days on end.
1h after last stomach-filling, Normal group intraperitoneal injection of saline 0.1ml/10g, remaining 5 groups of intraperitoneal injection 10%
Xanthine suspension 0.1ml/10g carries out modeling, is taken blood examination urine test acid value and is carried out to measurement result with plucking eyeball method after 0.5h
Analysis statistics, test result are as shown in table 1.
Table 1 causes mouse hyperuricemia test to xanthine
It is made it can be seen from the test data in table 1 by the hyperuricemia that the array of model group can be seen that mouse
Mould success, and compared with model group, the blood uric acid value of the mouse of test group 1~3 and control group is all substantially reduced, in this display
Stating 4 groups of groups has effect for the blood uric acid value decline of mouse, wherein compared with the control group with the test group of concentration for mouse
Blood uric acid value reducing effect it is more preferable, also, with test group concentration increase, it is more preferable for blood uric acid value reducing effect.
Two, mouse capillary permeability is tested
Test object and drug: taking healthy mice, and 200 ± 5g of weight, is randomly divided into 5 groups by 50；Take the embodiment of the present invention
3 sample is dense during test group 1 is high concentration dosage group (suitable crude drug amount 15g/75ml), test group 2 is as test group 1~3
Spend dosage group (suitable crude drug amount 10g/75ml) and 3 low concentration dosage group of test group (suitable crude drug amount 5g/75ml), dexamethasone
As positive controls, blank control group.
In addition to blank control group gives distilled water, the composition of remaining each group corresponding dosage, once a day, continuous 10d is given
Dose is 20ml/kg, after last dose 1h, 0.25% Evans blue 0.1ml/10g of tail vein injections, and intraperitoneal injection 0.6%
After glacial acetic acid 0.1ml/10g, 15min, cervical dislocation is put to death, and injects 6ml normal saline flushing abdominal cavity, peritoneal fluid 3000r/
Min is centrifuged 10min, goes supernatant to be measured, the results are shown in Table 2.
The test of 2 mouse capillary permeability of table
| Group | Quantity | Dosage (g/kg) | Peritoneal fluid absorbance value |
| Blank control group | 10 | / | 0.47±0.05 |
| Positive controls | 10 | 0.0068 | 0.24±0.06 |
| Test group 1 | 10 | 15 | 0.33±0.05 |
| Test group 2 | 10 | 10 | 0.36±0.03 |
| Test group 3 | 10 | 5 | 0.38±0.09 |
From the test data in table 2 it is recognised that compared with blank control group, the embodiment of the present invention 3 prepare prevention and
The pharmaceutical composition test group 1~3 for treating gout is inhibited for mouse capillary permeability caused by acetic acid, shows
Show that the pharmaceutical composition of the prevention and treatment gout of preparation of the embodiment of the present invention has mitigation acetic acid induced mice capillary logical
The raising of permeability.
Three, chmice acute urarthritis is tested
Examination object and drug: healthy mice is taken, 200 ± 5g of weight, is randomly divided into 5 groups by 50；Take the embodiment of the present invention 4
Sample as test group 1~3, test group 1 be high concentration dosage group (12g/kg), test group 2 be middle concentration dose group (8g/
Kg) and 3 low concentration dosage group (4g/kg) of test group, colchicin are as positive controls (0.9mg/kg), blank control group,
In addition to blank control group gives distilled water, remaining each group gives the composition of corresponding dosage, 1 time a day, dosage 10ml/
Kg, continuous 10d.1h after last medicine, toes behind 0.2mlMSU (50mg/ml) injection mouse right side are subcutaneous, with toes volumetric measurement
Instrument measure injection respectively before, 1,5,24 and 30h mouse toes and calculate its swelling with formula to ankle-joint volume after injection.
10% chloraldurate 3.2ml/kg anesthetized mice is injected intraperitoneally after 30h, is cutting right foot at 0.5cm on right ankle-joint, claims
Weight, and peeling is carried out, tissue and liquid are taken out by it and carries out isomerization processing under corresponding condition, and are surveyed under the conditions of 278nm
Its fixed absorbance value (A) (test data is as shown in table 3)
The test of 3 chmice acute urarthritis of table
The test data of table 3 is shown: the pharmaceutical composition for the prevention and treatment gout that when 1h and 5h prepared by the embodiment of the present invention 3
Object may be thus the inhibition of the foot swelling to mouse caused by MSU since action time is shorter according to a group colchicin with the positive
Effect is compared to weaker；And with the growth of effect, to for 24 hours with 30h each group for the inhibition of the foot swelling of mouse caused by MSU
Effect is remarkably reinforced, also, compared with positive controls, the inhibiting effect general effect of the degree swollen for mouse foot of test group 1~3
More preferably, inhibitory effect becomes apparent from, and function and effect are more preferable；Also, with the prevention and treatment gout of the preparation of the embodiment of the present invention 3
The concentration of pharmaceutical composition increases, more preferable for the inhibitory effect of degree of paw swelling.
Finally it should be noted that the above embodiments are merely illustrative of the technical solutions of the present invention, rather than the present invention is protected
The limitation of range is protected, although explaining in detail referring to preferred embodiment to the present invention, those skilled in the art are answered
Work as understanding, it can be with modification or equivalent replacement of the technical solution of the present invention are made, without departing from the reality of technical solution of the present invention
Matter and range.
Claims (10)
1. a kind of pharmaceutical composition for preventing and treating gout, which is characterized in that score meter includes following raw material by weight: 4~
11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9 parts
The coptis, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos and auxiliary material are several.
2. a kind of pharmaceutical composition for preventing and treating gout, which is characterized in that score meter by weight is made of following raw material: 4
~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9
Part coptis, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas and auxiliary material are several.
3. a kind of pharmaceutical composition for preventing and treating gout, which is characterized in that score meter by weight is made of following raw material: 4
~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9
Part coptis, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 parts of radix scutellariaes and auxiliary material are several.
4. a kind of pharmaceutical composition for preventing and treating gout, which is characterized in that score meter by weight is made of following raw material: 4
~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9
Part coptis, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 parts of rhizoma atractylodis and auxiliary material are several.
5. a kind of pharmaceutical composition for preventing and treating gout, which is characterized in that score meter by weight is made of following raw material: 4
~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9
Part coptis, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 portions of rhizoma alismatis and auxiliary material are several.
6. a kind of pharmaceutical composition for preventing and treating gout, which is characterized in that score meter by weight is made of following raw material: 4
~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9
Part coptis, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 portions of rhizoma alismatis, 3~8 portions of oriental wormwoods and auxiliary material are several.
7. a kind of pharmaceutical composition for preventing and treating gout, which is characterized in that score meter by weight is made of following raw material: 4
~11 portions of Selaginella tamariscinas, 5~12 parts of polygonum cuspidates, 3~8 parts of rheum officinales, 5~13 parts of ginkgo leaves, 6~13 parts of Radix Salviae Miltiorrhizaes, 5~13 parts of radix paeoniae rubras, 3~9
Part coptis, 3~10 portions of Radix Glycyrrhizaes, 4~12 parts of Poria cocos, 3~9 portions of evodia rutaecarpas, 2~8 portions of rhizoma alismatis, 3~10 parts of Radix Astragalis and auxiliary material are several.
8. a kind of pharmaceutical composition of prevention and treatment gout according to claims 1 to 7, which is characterized in that described
Auxiliary material is maltodextrin and sucrose.
9. a kind of pharmaceutical composition preparation method for preventing and treating gout according to claim 1, which is characterized in that packet
Containing following steps:
S1. raw material screening is carried out by formula, and gets out various raw material；
S2. it by various medicinal materials, is crushed, and impregnates 30~45min in warm water；
S3. the medicinal material after above-mentioned immersion is subjected to refluxing extraction, first high-temperature boiling, until keeping 5~10min after boiling, then again
35~50min is decocted with 50~60 DEG C of small fires；
S4. then, medical fluid and the dregs of a decoction being separated, collects medical fluid, the water for continuing to measure the dregs of a decoction with 8~12 times extracts the dregs of a decoction, first boils,
70~85 DEG C are then kept the temperature at, 50~60min is extracted, is extracted 2~3 times；
S5. then, filtrate is taken, filter residue is abandoned, medical fluid is condensed into the medicinal extract that density is 1.25~1.35 (60 DEG C) by merging filtrate；
S6. then, medicinal extract is mixed with auxiliary material, pelletized by granulator, tabletting and packing to get.
10. a kind of application of the pharmaceutical composition of prevention and treatment gout according to claims 1 to 7, which is characterized in that
The pharmaceutical composition of the prevention and treatment gout is used to prepare prevention and anti-gout drugs.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910786722.7A CN110384746A (en) | 2019-08-23 | 2019-08-23 | A kind of pharmaceutical composition and its preparation method and application preventing and treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910786722.7A CN110384746A (en) | 2019-08-23 | 2019-08-23 | A kind of pharmaceutical composition and its preparation method and application preventing and treating gout |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110384746A true CN110384746A (en) | 2019-10-29 |
Family
ID=68289244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910786722.7A Pending CN110384746A (en) | 2019-08-23 | 2019-08-23 | A kind of pharmaceutical composition and its preparation method and application preventing and treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110384746A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107468955A (en) * | 2017-09-06 | 2017-12-15 | 大连医科大学 | Treat the Chinese medicine and preparation method of urarthritis |
| CN109200122A (en) * | 2018-11-14 | 2019-01-15 | 南方医科大学深圳医院 | It is a kind of for eliminating the pharmaceutical composition and its application of red and swollen pain |
-
2019
- 2019-08-23 CN CN201910786722.7A patent/CN110384746A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107468955A (en) * | 2017-09-06 | 2017-12-15 | 大连医科大学 | Treat the Chinese medicine and preparation method of urarthritis |
| CN109200122A (en) * | 2018-11-14 | 2019-01-15 | 南方医科大学深圳医院 | It is a kind of for eliminating the pharmaceutical composition and its application of red and swollen pain |
Non-Patent Citations (3)
| Title |
|---|
| 刘维等: "中药内服治疗痛风性关节炎规律分析 ", 《中华中医药杂志》 * |
| 周珏平: "泻心汤加布洛芬治疗急性痛风60例观察", 《实用中医药杂志》 * |
| 陈维佳: "治疗痛风的中药筛选及作用机制研究", 《中国博士学位论文全文数据库医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102205107B (en) | Chinese medicinal preparation for treating duodenal ulcer and preparation method thereof | |
| CN102178800B (en) | Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN102600423B (en) | Preparation method of Chinese medicine for treating hepatic fibrosis | |
| CN104352991A (en) | Traditional Chinese medicine preparation for treating gout and preparation method thereof | |
| CN102205108B (en) | Traditional Chinese medicine preparation for treating gastric ulcer and preparation method thereof | |
| CN103719495B (en) | A kind of great burdock achene hypoglycemic health protection tea and preparation method thereof | |
| CN106266463A (en) | A kind of Chinese medicine composition for treating hyperuricemia and application thereof | |
| CN104524106A (en) | Traditional Chinese medicine preparation for treating prostatitis and prostatic hyperplasia and preparation method thereof | |
| CN103120732B (en) | Chinese medicinal composition for treating jaundice and preparation method thereof | |
| CN103083592A (en) | Traditional Chinese medicine for treating gouty arthritis | |
| CN106039109A (en) | Traditional Chinese medicinal liquor for preventing and treating cold dampness accumulation pattern rheumatoid arthritis | |
| CN105287748A (en) | Traditional Chinese medicine preparation for treating hyperuricemia and preparation method thereof | |
| CN104547902A (en) | Application of traditional Chinese preparation in preparation of drugs used for treating chronic enteritis and appendicitis | |
| CN104547798A (en) | Traditional Chinese medicine preparation for treating chronic enteritis and appendicitis and preparation method thereof | |
| CN102198261B (en) | Chinese medicinal preparation for treating elder chronic colitis and preparation method thereof | |
| CN103908603B (en) | A kind of Chinese medicine composition treating gout and preparation method thereof | |
| CN110384746A (en) | A kind of pharmaceutical composition and its preparation method and application preventing and treating gout | |
| CN103585495B (en) | Capsule for treating diabetic kidney damage | |
| CN105597033A (en) | Traditional Chinese medicine preparation for treating hepatolenticular degeneration | |
| CN115554379B (en) | Liver-softening and stasis-removing granule | |
| CN103520538B (en) | A kind ofly treat the pharmaceutical composition that diabetes cause kidney damage | |
| CN103495065B (en) | Enema particles for treating diabetic nephropathy and preparation method for enema particles | |
| CN102935151B (en) | Medicine composition for protecting liver and lowering transaminase and preparation method and application thereof | |
| CN105168844A (en) | Medicine for treating portal hypertension postoperative treating thrombosis | |
| CN105663838A (en) | Traditional Chinese medicine for treating choledocholithiasis by combining epidural anesthesia and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191029 |